Brought to you by 
DePuy AcroMed licenses BMP technology from Biopharm
27 May 2015
Executive Summary
Biopharm GMBH (drug discovery for orthopedics and neurodegenerative diseases) has licensed DePuy AcroMed (Johnson & Johnson's orthopedic devices and implants division) exclusive worldwide rights to its MP52-based bone morphogenic protein (BMP) compounds and technology portfolio to develop products for bone, cartilage, and soft tissue repair.
Deal Industry
- Pharmaceuticals
-
Medical Devices
- Biomaterials
-
Biotechnology
- Gene Therapy, Cell Therapy
- Large Molecule
Deal Status
- Final
Deal Type
-
Alliance
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
DePuy AcroMed licenses BMP technology from Biopharm
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice